{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:21:52Z","timestamp":1792142512986,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.4158\/ep171922.or","type":"journal-article","created":{"date-parts":[[2017,11,6]],"date-time":"2017-11-06T14:50:29Z","timestamp":1509979829000},"page":"143-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Insulin Glargine 300 U\/Ml is Associated with Less Weight Gain while Maintaining Glycemic Control and Low Risk of Hypoglycemia Compared with Insulin Glargine 100 U\/Ml in an Aging Population with Type 2 Diabetes"],"prefix":"10.1016","volume":"24","author":[{"given":"Medha N.","family":"Munshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ElenaV","family":"Nikonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP171922.OR_bb0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3111\/13696998.2011.610852","article-title":"Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs","volume":"14","author":"Fidler","year":"2011","journal-title":"J Med Econ"},{"key":"10.4158\/EP171922.OR_bb0015","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00125-002-0822-9","article-title":"Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes","volume":"45","author":"Cryer","year":"2002","journal-title":"Diabetologia"},{"key":"10.4158\/EP171922.OR_bb0020","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.4158\/EP171922.OR_bb0025","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.4158\/EP171922.OR_bb0030","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00592-015-0727-y","article-title":"Risk of and risk factors for hypoglycemia and associated arrhythmias in patients with type 2 diabetes and cardiovascular disease: a cohort study under real-world conditions","volume":"52","author":"Pistrosch","year":"2015","journal-title":"Acta Diabetol"},{"key":"10.4158\/EP171922.OR_bb0035","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1463-1326.2012.01583.x","article-title":"Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes","volume":"14","author":"Johnston","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP171922.OR_bb0040","first-page":"243","article-title":"Association between hypoglycemia and fall-related events in type 2 diabetes mellitus: analysis of a U.S. commercial database","volume":"21","author":"Kachroo","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"10.4158\/EP171922.OR_bb0045","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/(SICI)1096-9136(199805)15:5<398::AID-DIA595>3.0.CO;2-B","article-title":"Perceived symptoms of hypoglycaemia in elderly type 2 diabetic patients treated with insulin","volume":"15","author":"Jaap","year":"1998","journal-title":"Diabet Med"},{"key":"10.4158\/EP171922.OR_bb0050","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/jamainternmed.2014.1824","article-title":"National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011","volume":"174","author":"Lipska","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.4158\/EP171922.OR_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/DMSO.S26980","article-title":"Insulin detemir for the treatment of obese patients with type 2 diabetes","volume":"5","author":"Hollander","year":"2012","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.4158\/EP171922.OR_bb0060","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2337\/dc12-2258","article-title":"The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988\u20132010","volume":"36","author":"Stark Casagrande","year":"2013","journal-title":"Diabetes Care"},{"key":"10.4158\/EP171922.OR_bb0065","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2337\/dc14-0006","article-title":"New insulin glargine 300 Units \u00b7 mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units \u00b7 mL-1","volume":"38","author":"Becker","year":"2015","journal-title":"Diabetes Care"},{"key":"10.4158\/EP171922.OR_bb0070","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/dom.12415","article-title":"Single-dose new insulin glargine 300 U\/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes","volume":"17","author":"Shiramoto","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP171922.OR_bb0075","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.2337\/dc14-0991","article-title":"New insulin glargine 300 units\/mL versus glargine 100 units\/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)","volume":"37","author":"Riddle","year":"2014","journal-title":"Diabetes Care"},{"key":"10.4158\/EP171922.OR_bb0080","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2337\/dc14-0990","article-title":"New insulin glargine 300 units\/mL versus glargine 100 units\/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)","volume":"37","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Diabetes Care"},{"key":"10.4158\/EP171922.OR_bb0085","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/dom.12438","article-title":"New insulin glargine 300 U\/ml compared with glargine 100 U\/ml in insulin-na\u00efve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)","volume":"17","author":"Bolli","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP171922.OR_bb0090","unstructured":"World Health Organization (WHO)Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/66040\/1\/WHO_NCD_NCS_99.2.pdf. Accessed October 1, 2016."},{"key":"10.4158\/EP171922.OR_bb0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/dia.2016.0454","article-title":"Efficacy and Safety of Insulin Glargine 300 U\/mL Versus Insulin Glargine 100 U\/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures","volume":"19","author":"Lingvay","year":"2017","journal-title":"Diabetes Technol Ther"},{"key":"10.4158\/EP171922.OR_bb0100","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMp068177","article-title":"Obesity and diabetes in the developing world--a growing challenge","volume":"356","author":"Hossain","year":"2007","journal-title":"N Engl J Med"},{"key":"10.4158\/EP171922.OR_bb0105","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.2337\/dc12-1391","article-title":"Determinants of weight gain in the action to control cardiovascular risk in diabetes trial","volume":"36","author":"Fonseca","year":"2013","journal-title":"Diabetes Care"},{"key":"10.4158\/EP171922.OR_bb0110","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1463-1326.2006.00686.x","article-title":"Insulin-associated weight gain in diabetes--causes, effects and coping strategies","volume":"9","author":"Russell-Jones","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP171922.OR_bb0115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1758-5996-5-56","article-title":"Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational study","volume":"5","author":"Yale","year":"2013","journal-title":"Diabetol Metab Syndr"},{"key":"10.4158\/EP171922.OR_bb0120","unstructured":"World Health Organization (WHO)Global Database on Body Mass Index. Available at: http:\/\/apps.who.int\/bmi\/index.jsp?introPage=intro_3.html. Accessed July 6, 2015."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2035401X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2035401X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:05:14Z","timestamp":1761516314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2035401X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1530891X2035401X"],"URL":"https:\/\/doi.org\/10.4158\/ep171922.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insulin Glargine 300 U\/Ml is Associated with Less Weight Gain while Maintaining Glycemic Control and Low Risk of Hypoglycemia Compared with Insulin Glargine 100 U\/Ml in an Aging Population with Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP171922.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}